ImmunoGen

-$0.07 (-1.98%) Today
$0.00 (0.00%) As of 9:59 PM UTC after-hours

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ImmunoGen and other ETFs, options, and stocks.

About IMGN

ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151.

CEO
Mark Joseph Enyedy
Employees
106
Headquarters
Waltham, Massachusetts
Founded
1981

IMGN Key Statistics

Market cap
765.26M
Price-Earnings ratio
—
Dividend yield
—
Average volume
5.57M
High today
$3.63
Low today
$3.36
Open price
$3.53
Volume
3.26M
52 Week high
$7.77
52 Week low
$3.36

IMGN News

MarketWatchMay 23

ImmunoGen's stock is up 12% after the FDA accepts application for new ovarian-cancer therapy

Shares of ImmunoGen Inc. IMGN, +1.42% jumped 12.0% in premarket trading on Monday after the company said the Food and Drug Administration accepted an applicatio

IMGN Earnings

-$1.71
-$1.09
-$0.46
$0.16
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Q2 FY22
Estimated
— per share
Actual
Expected Jul 29, Pre-Market
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure